Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Leerink downgraded Rocket Pharmaceuticals (RCKT) to Market Perform from Outperform with a price target of $8, down from $37, after the company ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

On Tuesday, Leerink Partners made a significant adjustment to the price target of Lexeo Therapeutics (NASDAQ: LXEO) shares, reducing it to $10.00 from the previous $16.00, while still maintaining ...

A rough earnings report raised troubling questions about UHG’s future, and so did the resignation of CEO Andrew Witty.

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Leerink Partners on Friday upgraded Fulcrum Therapeutics, Inc. (NASDAQ:FULC) to Outperform from Market Perform, and raised the stock’s price target to $12 per share from $4. The analyst cited a ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to an acquisition by Transcarent. The firm views the ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...

Leerink Partners, an advisory firm specializing in health-care deals, has hired two investment bankers from Evercore Inc. Bernhard Sakmann and Justin Reed will be joining Leerink and will be based ...